Marrow-Sparing Effects of
\(^{117m}\)Sn(4+)Diethylenetriaminepentaacetic Acid
for Radionuclide Therapy of Bone Cancer

Anupam Bishayee, Dandamudi V. Rao, Suresh C. Srivastava, Lionel G. Bouchet, Wesley E. Bolch, and Roger W. Howell

Division of Radiation Research, Department of Radiology, University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark, New Jersey; Medical Department, Brookhaven National Laboratory, Upton, New York; and Department of Nuclear and Radiological Engineering, University of Florida, Gainesville, Florida

Several bone-seeking radionuclides (\(^{32}\)P, \(^{85}\)Sr, \(^{186}\)Re, and \(^{153}\)Sm) have been used to treat bone pain. The limiting factor in this modality is marrow toxicity. Our hypothesis is that marrow toxicity can be reduced while maintaining therapeutic efficacy using radionuclides that emit short-range \(\beta\) particles or conversion electrons (CEs). A recent study on 47 patients using the short-range CE emitter \(^{117m}\)Sn(4+)diethylenetriaminepentaacetic acid \((^{117m}\)Sn(4+)DTPA) supports this hypothesis. The hypothesis is now tested using \(^{117m}\)Sn(4+)DTPA in a mouse femur model.

Methods: The survival of granulocyte–macrophage colony-forming cells (GM-CFCs) in femoral marrow is used as a biologic dosimeter for bone marrow. The dosimeter is calibrated by irradiating mice with exponentially decreasing dose rates of \(^{137}\)Cs \(\gamma\)-rays with a dose-rate decrease half-time, \(T_d\), equal to the effective clearance half-time of \(^{117m}\)Sn(4+)DTPA from the femur (222 h). When \(T_d = 222\) h, the mean absorbed dose required to achieve a survival fraction of 37% is 151 cGy. After calibration, \(^{117m}\)Sn(4+)DTPA is administered and GM-CFC survival is determined as a function of injected activity. These data are used to experimentally determine the mean absorbed dose to the femoral marrow per unit injected activity. The kinetics of radioactivity in the marrow, muscle, and femoral bone are also determined. Finally, a theoretic dosimetry model of the mouse femur is used, and the absorbed doses to the femoral marrow and bone are calculated.

Results: The experimental mean absorbed dose to the femoral marrow per unit injected activity of \(^{117m}\)Sn(4+)DTPA is 0.043 cGy/kBq. The theoretic mean absorbed dose to the femoral bone per unit injected activity is 1.07 cGy/kBq. If these data are compared with those obtained previously for \(^{32}\)P-orthophosphate, the radiochemical \(^{117m}\)Sn(4+)DTPA yields up to an 8-fold therapeutic advantage over the energetic \(\beta\) emitter \(^{32}\)P.

Conclusion: The CE emitter \(^{117m}\)Sn offers a large dosimetric advantage over energetic \(\beta\)-particle emitters for alleviating bone pain, and possibly for other therapeutic applications, while minimizing marrow toxicity.

Key Words: bone; pain; metastases; radionuclides; granulocyte–macrophage colony-forming cells; chronic irradiation; dose–response; dosimetry; EGS4; \(^{32}\)P; \(^{85}\)P; \(^{117m}\)Sn; therapy


Several bone-seeking radiopharmaceuticals have been used to treat bone pain caused by osteometastases (1–4). About 65%–85% of patients experience substantial pain relief by these therapeutic agents (1,5). Radioactive phosphorus \((^{32}\)P) was the first radionuclide to be used in bone pain palliation therapy (6); however, other radiochemicals, including \(^{89}\)Sr-chloride (2,7,8), \(^{85}\)Sr-chloride (9), \(^{186}\)Re-1,1-dihydroxyethylidene diphosphonate \((10–12)\), and \(^{153}\)Sm-ethylendiaminetetramethylene phosphonic acid \((13–15)\), have been used subsequently for this purpose.

The major dose-limiting factor in this modality is bone marrow toxicity, which leads to a decrease in peripheral blood cell counts (1,16). The bone marrow absorbed dose is imparted by radiation emitted by radioactive decays in four principal source compartments: marrow, endosteum, bone matrix, and all other surrounding organs. The radiochemicals that have been used (or proposed for use) in bone palliation therapy localize predominantly in the skeletal tissues and emit a high yield of \(\beta\) particles (Table 1). Therefore, the marrow absorbed dose can be primarily attributed to decays in the first three compartments. Given that these radiopharmaceuticals selectively localize in bone and concentrate in the bony lesions, it has been suggested that use of low-energy electron emitters (e.g., short range) might reduce the bone marrow toxicity while selectively increasing the dose to the bone matrix (17–20). In an earlier study in mice using the colony-forming units per spleen assay, therapeutic doses of \(^{117m}\)Sn were shown to offer an almost 30-fold bone marrow–sparing advantage over \(^{32}\)P (21). Using a murine model, Goddu et al. (20) showed that the low-energy \(\beta\) emitter \(^{33}\)P offers a 3- to 6-fold therapeutic advantage over the energetic \(\beta\) emitter \(^{32}\)P. Atkins et al. (22) and Srivastava et al. (23) used the low-energy conversion electron (CE) emitter \(^{117m}\)Sn \((^{117m}\)Sn(4+)dihydroxyethylidene diphosphonate (DTPA)) to treat bone pain in patients and found effective pain relief with no significant myelotoxicity.

Although pharmacokinetic data have been obtained for \(^{117m}\)Sn(4+)DTPA (23–25), to our knowledge, no detailed study has been performed to study the bone and bone marrow dosimetry characteristics of this radionuclide. This
orthophosphate, respectively, for palliation of bone pain.

**Radionuclide Kinetics and Optimal Day for GM-CFC Survival Assay**

The biokinetics of \(^{117m}\text{Sn}(4 +)\)DTPA was obtained as follows. Animals, in groups of four, were injected intravenously with an equal activity of radiochemical (240 kBq/0.2 mL). Animals were killed on 0.21, 0.67, 1.25, 2.29, 5, 7, 14, 21, and 30 d after injection and the femurs were resected. The muscle surrounding the femur was removed and the muscle and femur were transferred to separate preweighed 12 × 75 mm glass tubes. The activities in the muscle and femur were determined using a NaI scintillation well counter with window levels set on the 156.0- and 158.6-keV photopeaks (combined yield, 0.885; efficiency, 0.62) of \(^{117m}\text{Sn}\). The marrow was flushed from the femurs, and the activity in aliquots of the marrow suspension along with the activity remaining in the femur were determined. Femur and muscle weights were determined in each case. The activities in muscle, bone matrix, and marrow compartments were thus determined as a function of time after injection.

The optimal day to assay GM-CFC survival (day after injection on which nadir occurs) was determined as follows. Animals, in groups of four, were injected intravenously with an equal amount of radiochemical on 5, 7, and 9 d before the date of killing. In addition, two untouched groups were maintained as control animals. Experiments were performed for two different injection activities (370 and 5846 kBq/0.2 mL) to ensure that injected activity did not influence the optimal day. All groups were killed on the same day and assayed for GM-CFC survival; the survival fraction compared with control animals was plotted as a function of time after injection.

**GM-CFC Survival Assay**

The experimental protocols adopted from Metcalfe (28) and described in our earlier article (27) were used for determination of GM-CFC survival. Preparation of the different culture media required for the assay has been described (27). Briefly, the animals were killed by cervical dislocation and immersed in 70% ethanol, and the femurs were separated under aseptic conditions (laminar flow hood) using sterile instruments. Marrow from these femurs was flushed with 1 mL wash medium into a 50-mL tube using a 3-mL syringe fitted with a 21-gauge needle. After aspirating the medium through the femur shaft several times, an additional 3 mL fresh medium were flushed through the femur. The cell suspension was centrifuged, the supernatant was decanted, and the pellet was resuspended in 5 mL wash medium. The mononucleated cell fraction was separated from the crude bone marrow suspension by gently layering 5-mL cell suspension on top of 3.5 mL Histopaque-1077 (Sigma Chemical Co., St. Louis, MO) and centrifuging at 400g for 30 min at 4°C. The mononucleated cell layer was removed carefully with a 3-mL syringe, washed three times with 15 mL wash medium, and resuspended in 2 mL double-strength culture medium. The number of mononucleated cells corresponding to each group was counted using a model ZM cell counter (Coulter Electronics, Hialeah, FL). Three dilutions of the resulting mononucleated cells were plated for colony formation by mixing with equal volumes of double-strength culture medium and 0.6% Bacto agar solution (DIFCO, Detroit, MI) in the presence of 1200 U (20 µL) of granulocyte–macrophage colony-stimulating factor (Sigma). The plates remained at room temperature until the agar gelled firmly (10–15 min), whereupon they were transferred to an incubator at 37°C with 100% humidity, 5% CO₂:95% air, for 7 d to allow colony formation. The resulting GM-CFC colonies were
GM-CFC Survival Versus Femoral Activity

GM-CFC survival was determined as a function of injected activity for $^{117m}$Sn($4 \pm$)DTPA. Six groups (four mice per group) of mice were injected with a fixed 0.2-mL volume containing different activities of the radiochemical. The animals were killed on the optimal day (seventh day after injection; Results) and assayed for GM-CFC survival. The femoral bones, having been purged of marrow for the survival assay, were dried, weighed, and assayed for activity content as described. Activities in the flushed bone marrow samples were also determined. The extrapolated initial activities were obtained by correcting these activities to the time of injection using the physical half-life of the radionuclides and the effective half-times of the radiochemical in the femurs obtained in the biokinetics experiments.

Calibration of Biologic Dosimeter

The biologic dosimeter, survival of GM-CFC (27), was calibrated using our custom-designed low-dose-rate $^{137}$Cs irradiator (equipped with computer-controlled mercury attenuator system), which facilitates the delivery of exponentially decreasing dose rates (26). This irradiator allows simultaneous irradiation of mice (groups of four) with different initial dose rates by placing different groups of mice at different distances from the $^{137}$Cs source. Although the initial dose rates were different for each group of mice, the dose rates to each group were exponentially decreased using a dose-rate decrease half-time of 9.2 d, which is equal to the effective half-time of the radiochemical in the femoral bone (Results). Animals were taken out of the irradiator on the optimal day (see above), killed, and assayed for GM-CFC cell survival.

Radionuclide Kinetics

Figure 1 shows the effective uptake and clearance of $^{117m}$Sn($4 \pm$)DTPA in mouse femoral bone, femoral marrow, and muscle surrounding the femur after intravenous administration of this radiochemical. The kinetics data were least-squares fit to the two-component exponential function given by Equation 2.

$$%IA/g = k(a \exp(-0.693t/T_{e1}) + (1-a) \exp(-0.693t/T_{e2}))$$  

Eq. 2

The fitted values for muscle are $k = 0.65$, $a = 0.94$, $T_{e1} = 0.50$ d, and $T_{e2} = 5.0$ d. A single-component fit emerges for bone and marrow. For femoral marrow, $a = 1$, $k = 0.81$, and $T_{e1} = 10.5$ d. Finally, for femoral bone, $a = 1$, $k = 42.3$, and $T_{e1} = 9.2$ d.

The extrapolated initial activity, $A_{inj}$, in the femoral bone is

<table>
<thead>
<tr>
<th>TABLE 2</th>
<th>Theoretic S Values for $^{117m}$Sn (cGy/kBq h)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source</td>
<td>Marrow</td>
</tr>
<tr>
<td>---------</td>
<td>--------</td>
</tr>
<tr>
<td>Marrow</td>
<td>0.635</td>
</tr>
<tr>
<td>Endosteum</td>
<td>0.316</td>
</tr>
<tr>
<td>Matrix</td>
<td>0.050</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.000292</td>
</tr>
</tbody>
</table>

*Calculated using theoretic model described in (20).

<table>
<thead>
<tr>
<th>TABLE 3</th>
<th>Theoretic Absorbed Dose to Marrow from $^{117m}$Sn($4 \pm$)DTPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source</td>
<td>$A_{inj}$(source)* (kBq h)</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Bone</td>
<td>4310</td>
</tr>
<tr>
<td>Marrow</td>
<td>53.7</td>
</tr>
<tr>
<td>Muscle</td>
<td>208</td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
</tbody>
</table>

*Cumulated activity is integrated from $t = 0$ to $t = 7$ d, the GM-CFC survival nadir.
†Calculated using Equation 1 with bone marrow as target region.
‡Assumes radioactivity in bone is localized in bone matrix.
plotted as a function of the injected activity, $A_{\text{Inj}}$, in Figure 2. The extrapolated initial activity was linearly dependent on the injected activity according to the relationship,

$$ A_0 = 0.0086 A_{\text{Inj}}, \quad \text{Eq. 3} $$

These results indicate that 0.86% of the injected $^{117m}\text{Sn}$ quickly localizes in each femoral bone.

**Optimal Day**

The optimal day to assay GM-CFC survival is the day on which the survival is minimum (nadir). The survival of GM-CFCs as a function of time after injection of $^{117m}\text{Sn}(4+)\text{DTPA}$ is shown in Figure 3. As in our previous studies with $^{90}\text{Y}$-citrate, $^{32}\text{P}$-orthophosphate, and $^{33}\text{P}$-orthophosphate, the survival fraction reaches a minimum on the seventh day after injection and it is independent of the injected activity over the range studied ($20, 27$).

**GM-CFC Survival Versus Activity**

Figure 4 shows the GM-CFC survival fraction as a function of both the injected activity and the extrapolated initial femoral bone activity. The data were least-squares fit to a simple exponential function given by Equation 4.

$$ SF = \exp(-A/A_{0,37}) = \exp(-A_{\text{Inj}}/A_{\text{Inj},37}), \quad \text{Eq. 4} $$

where $SF$ is the fraction of GM-CFC survival, $A_0$ is the extrapolated initial femoral bone activity, $A_{0,37}$ is the extrapolated initial femoral bone activity required to achieve 37% GM-CFC survival, $A_{\text{Inj}}$ is the activity injected into each femoral bone, and $A_{\text{Inj},37}$ is the injected activity required to achieve 37% GM-CFC survival. The fitted value for $A_{\text{Inj},37}$ was 30.2 ± 0.8 kBq per femoral bone and the $A_{\text{Inj},37}$ was 3546 ± 88 kBq.

**Calibration of Biologic Dosimeter**

The survival of GM-CFCs as a function of initial dose rate (cGy/h) delivered by the $^{137}\text{Cs}$ irradiator is shown in Figure 5 for a dose-rate decrease half-time, $T_d = 9.2$ d. The data were least-squares fit to Equation 5:

$$ SF = \exp(-r_0/r_{0,37}), \quad \text{Eq. 5} $$

where $r_0$ is the initial dose rate (cGy/h) and $r_{0,37}$ is the initial dose rate required to achieve 37% GM-CFC survival. The fitted value of $r_{0,37}$ was 1.17 ± 0.05 cGy/h.

The cumulated absorbed dose, $D$, delivered by the irradiator over the 7-d irradiation period is given by:

$$ D = r_0 \int_0^{168} \exp(-0.693t/T_d) \, dt. \quad \text{Eq. 6} $$

The initial dose rate $r_0$ was different for each group of animals. The ordinate and upper abscissa of Figure 5 show the GM-CFC survival as a function of absorbed dose received by the marrow. A least-squares fit of the data to the function,

$$ SF = \exp(-D/D_{37}), \quad \text{Eq. 7} $$

yields the dose required to achieve 37% survival, $D_{37}$. For the dose-rate decrease half-time of 222 h, $D_{37}$ = 151 ± 7 cGy. As indicated above, this half-time corresponds to the...
The effective clearance half-time of $^{117m}$Sn(4+)DTPA from the femoral bone. This $D_{37}$ can be compared with our previously obtained values of $144 \pm 15, 132 \pm 12, 129 \pm 3, \text{ and } 133 \pm 10 \text{ cGy}$ for dose-rate decrease half-times of 62, 255, and 425 h and $\approx$ (constant dose rate), respectively (20,27).

This new datum supports our earlier conclusion that differences in dose rate (0.25–8 cGy/h) among these various dose-rate decrease half-times do not play a major role in determining the survival of GM-CFCs over the range of initial dose rates, total doses, and irradiation times considered in these experiments (20). Rather, the total dose delivered is of primary importance. This conclusion is based on integration of the absorbed dose rate over 7 d (Eq. 6). Very disparate $D_{37}$ values would emerge if the integration was performed to infinity (e.g., integration of constant dose rate to infinite time yields infinite absorbed dose), thereby emphasizing the importance of integrating over a time that is relevant to the biologic endpoint that is studied (30,31).

### Experimental and Theoretic Mean Absorbed Doses

The mean absorbed dose to murine femoral marrow from $^{117m}$Sn is principally from decays that occur in two compartments: femoral marrow and femoral bone matrix. The response of the biologic dosimeter (GM-CFC survival) registers the total dose from decays that occur in these source regions. By equating Equations 4 and 7, the experimental mean absorbed dose to bone marrow per unit injected activity $D(\text{marrow})/A_{\text{inj}}$ is given by:

$$D(\text{marrow})/A_{\text{inj}} = D_{37}/A_{\text{inj},37}.$$  

Eq. 8

The experimental $D(\text{marrow})/A_{\text{inj}}$ for $^{117m}$Sn(4+)DTPA is $0.043 \pm 0.002 \text{ cGy/kBq}$.

The theoretic absorbed dose to femoral marrow per unit injected activity, assuming a uniform distribution of $^{117m}$Sn in the femoral bone matrix, is calculated according to Equation 1 to be $D(\text{marrow})/A_{\text{inj}} = 0.071 \text{ cGy/kBq}$. This quantity is given in Table 3 along with a breakdown of the contributions from the various source compartments. The theoretic mean absorbed dose to the bone matrix $D(\text{matrix})/A_{\text{inj}} = 1.07 \text{ cGy/kBq}$ (Table 4).

### DISCUSSION

The effective clearance half-time from the femoral bone is 9.2 d for $^{117m}$Sn(4+)DTPA. Given that $^{117m}$Sn has a physical half-life of 13.9 d, this corresponds to a biologic clearance half-time of 27.2 d. This biologic half-time is somewhat longer than the half-time of 16.5 d observed by Swailem et al. (25) in BALB/c mice. Our data for bone may be compared with the data obtained for humans where no clearance from bone was observed (25). Interestingly, the effective clearance half-time from marrow (10.5 d) is slightly longer than from bone. It is possible that this long half-time may be due to radioactivity bound to small bone spicules that may be dislodged from the marrow cavity during the flushing procedure. Muscle surrounding the...
tissue. To compare the relative efficacy of two radiopharmaceuticals to palliate bone pain, estimates of both the absorbed dose to the marrow and the absorbed dose to healthy tissue. To compare the relative efficacy of two radiopharmaceuticals to palliate bone pain, estimates of both the absorbed dose to the marrow and the absorbed dose to the target regions that are responsible for the pain relief are required. However, the mechanisms by which radiation provides pain relief are poorly understood (5). A host of different mechanisms have been advanced; however, none has been definitively established (34,35). Therefore, the target has not been clearly established.

Even though the target for alleviation of bone pain is not well defined, one can estimate the relative efficacy of different radiopharmaceuticals for this modality by considering the bone matrix as the target region (20). Assuming that the bone matrix is the target region and that the cumulative activity is integrated to infinity, $D_{\text{matrix}}/A_{\text{inj}} = 1.07 \text{ cGy/kBq}$ (Table 4). These data, in conjunction with the

The principal factor that limits the use of radiopharmaceuticals for reduction of bone pain is myelotoxicity. This limitation is largely associated with the high-energy $\beta$ emitters that have been used to treat bone pain (e.g., $^{89}$Sr, $^{32}$P). The $\beta$ particles emitted by these radionuclides irradiate not only sites associated with reduction of pain but also the bone marrow. Several investigators have advocated the use of low-energy (i.e., short range) $\beta$ or CE emitters to reduce or eliminate myelotoxicity, and there is now a substantial amount of supporting clinical data (18,22,23,25,32,33). The ideal radiopharmaceutical would eliminate pain without causing deleterious effects to bone marrow or any other healthy tissue. To compare the relative efficacy of two radiopharmaceuticals to palliate bone pain, estimates of both the absorbed dose to the marrow and the absorbed dose to the target regions that are responsible for the pain relief are required. However, the mechanisms by which radiation provides pain relief are poorly understood (5). A host of different mechanisms have been advanced; however, none has been definitively established (34,35). Therefore, the target has not been clearly established.

Even though the target for alleviation of bone pain is not well defined, one can estimate the relative efficacy of different radiopharmaceuticals for this modality by considering the bone matrix as the target region (20). Assuming that the bone matrix is the target region and that the cumulative activity is integrated to infinity, $D_{\text{matrix}}/A_{\text{inj}} = 1.07 \text{ cGy/kBq}$ (Table 4). These data, in conjunction with the

<table>
<thead>
<tr>
<th>Source</th>
<th>$\tau^*$ (h)</th>
<th>$S_{\text{matrix -- source}}$ (cGy/kBq h)</th>
<th>$D_{\text{matrix}}/A_{\text{inj}}$† (cGy/kBq)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone</td>
<td>2.98</td>
<td>0.359</td>
<td>1.07</td>
</tr>
<tr>
<td>Marrow</td>
<td>0.041</td>
<td>0.0473</td>
<td>0.0019</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.0693</td>
<td>0.00305</td>
<td>0.000021</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>1.07</td>
</tr>
</tbody>
</table>

$^*$Residence time when cumulated activity is integrated from $t = 0$ to $t = \infty$.

† Calculated using Equation 1 with bone matrix as target region.
The experimental mean absorbed dose to bone marrow per unit injected activity, can be used to examine the capacity of $^{117m}$Sn(4+)DTPA to deliver a higher target-to-nontarget absorbed dose ratio than a given reference radiopharmaceutical. As previously defined, this can be quantified in terms of a relative advantage factor (RAF) with marrow serving as the nontarget region (20).

$$\text{RAF} = \frac{D_{(\text{target})}}{D_{(\text{marrow})}}_{^{117m}\text{Sn-DTPA}} / \frac{D_{(\text{target})}}{D_{(\text{marrow})}}_{\text{Reference}}. \quad \text{Eq. 9}$$

If $^{32}$P-orthophosphate is taken as the reference radiopharmaceutical, the earlier results of Goddu et al. (20) can be used to calculate the RAF. Using the same models, they obtained a theoretic $D_{(\text{matrix})}/A_{(\text{inj})} = 1.27 \text{ cGy/kBq}$ and an experimental $D_{(\text{marrow})}/A_{(\text{inj})} = 0.42 \text{ cGy/kBq}$ for $^{32}$P-orthophosphate (20). Therefore, a comparison of $^{117m}$Sn(4+)DTPA with $^{32}$P-orthophosphate yields an RAF of 4.2. If the theoretic marrow doses are used, then RAF values of 5.5 and 5.6 are obtained for $^{117m}$Sn(4+)DTPA and $^{33}$P-orthophosphate, respectively (Table 5). Similar RAF values were obtained when a theoretic model of human cortical bone was used (33). This indicates that there is a substantial advantage for both $^{117m}$Sn(4+)DTPA and $^{33}$P-orthophosphate over $^{32}$P-orthophosphate.

CONCLUSION

The experimental and theoretic approaches used in this study support the use of the low-energy electron emitter $^{117m}$Sn for alleviation of pain caused by metastatic disease in bone. This radionuclide offers a substantial therapeutic advantage over energetic $\beta$-particle emitters in that it has the potential to deliver high doses to bone while minimizing the absorbed dose to the bone marrow (17,18,22,32). Because of substantially reduced myelotoxicity, and an excellent safety profile (22,23,36,37), high-dose therapeutic administration of $^{117m}$Sn(4+) chelates could be potentially useful for the treatment of primary or metastatic bone malignancies and early-stage metastatic disease in bone.

ACKNOWLEDGMENTS

The authors thank Diatide, Inc., for providing the $^{117m}$Sn(4+)DTPA used in this study. This work was supported in part by U.S. Public Health Service grant CA-54891 and U.S. Department of Energy (DOE) grant DE-FG05–95ER62006. Work at Brookhaven National Laboratory was performed under U.S. DOE contract DE-AC02–98CH10886.

REFERENCES


<table>
<thead>
<tr>
<th>Radiopharmaceutical</th>
<th>$A_{(\text{inj})}^{37}$ (kBq)</th>
<th>$D_{(\text{marrow})}/A_{(\text{inj})}$</th>
<th>$\text{RAF}^\dagger$</th>
<th>$\text{RAF}^\ddagger$</th>
<th>$\tau_{(\text{muscle})}^\S$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{32}$P-orthophosphate</td>
<td>313 ± 29</td>
<td>0.42 ± 0.055</td>
<td>—</td>
<td>—</td>
<td>3.7</td>
</tr>
<tr>
<td>$^{33}$P-orthophosphate</td>
<td>2820 ± 425</td>
<td>0.047 ± 0.010</td>
<td>4.2</td>
<td>5.6</td>
<td>5.3</td>
</tr>
<tr>
<td>$^{117m}$Sn(4+)DTPA</td>
<td>3546 ± 88</td>
<td>0.043 ± 0.002</td>
<td>8.2</td>
<td>5.5</td>
<td>0.0693</td>
</tr>
</tbody>
</table>

*Experimental mean absorbed dose to femoral marrow per unit injected activity.
†Relative advantage factor based on experimental $D_{(\text{marrow})}/A_{(\text{inj})}$ and theoretic $D_{(\text{matrix})}/A_{(\text{inj})}$.
‡Relative advantage factor based on theoretic $D_{(\text{marrow})}/A_{(\text{inj})}$ and theoretic $D_{(\text{matrix})}/A_{(\text{inj})}$.
§Residence time in muscle after integrating to $\infty$.
¶Data taken from (20).


Marrow-Sparing Effects of $^{117m}$Sn(4+)Diethylenetriaminepentaacetic Acid for Radionuclide Therapy of Bone Cancer

Anupam Bishayee, Dandamudi V. Rao, Suresh C. Srivastava, Lionel G. Bouchet, Wesley E. Bolch and Roger W. Howell


This article and updated information are available at:
http://jnm.snmjournals.org/content/41/12/2043

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml

*The Journal of Nuclear Medicine* is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2000 SNMMI; all rights reserved.